Rubella

Rubella and Congenital Rubella Syndrome

Generalities
Agent	Rubella virus, genus Rubullovirus, family Togaviridae
Incubation period	14-17 days (range 14-21 days)
Period of transmissibility	- 7 days before rash and 4 days after rash onset - From congenital rubella: infants shed the virus for several months after birth
Reservoir	Humans
Modes of transmission	- Person-to-person: direct contact with droplets - Infants with Congenital Rubella Syndrome shed large quantities of virus in their pharyngeal secretions and urine. - Materno-foetal transmission: 90% of infants born to women infected with rubella during the 1st trimester. The risk of transmission is 10-20% by the 16th week, and rare after the 20th week.
Clinical presentation	- Febril maculo-papular rash - Complications: thrombocytopenia (1/3000), post-infectious encephalitis (1/6000), rarely chronic arthritis - Congenital Rubella Syndrome: Congenital malformation as deafness, cataracts, microphtalmia, congenital glaucoma, pigmentary retinopathy, nystagmus, microcephaly, meningo-encephalitis, mental retardation, patent ductus arteious, atrial or ventricular septal defects, other congenital heart disease, purpura, hepatosplenomegaly, jaundice, radiolucent bone disease
Resources
Case definitions	- MOPH circular no 12 (2013): Acquired Rubella - MOPH circular no 45 (2007): Congenital Rubella Syndrome
Forms	- Rash reporting form - CRS reporting form - Rash investigation form - CRS investigation form
Data	- Rubella 2021 - Rubella 2020 - Rubella 2019 - Rubella 2018 - Rubella 2017 - Rubella 2016 - Rubella 2015

...

All

ATC	Name	B/G	Ingredients	Dosage	Form	Price
R01AA07	OTRIVIN	B	Xylometazoline HCl - 0.05%	0.05%	Solution	260,705 L.L
R01AA07	OTRIVIN	B	Xylometazoline HCl - 0.05%	0.05%	Drops	181,419 L.L
G03CA03	OESTRODOSE	B	Estradiol (17 bêta estradiol anhydre) - 0.06%	0.06%	Gel	642,357 L.L
S01GX09	OLOHISTINE	G	Olopatadine (HCl) - 0.1%	0.1%	Solution	522,755 L.L
S01GX09	OLOPAT	G	Olopatadine (HCl) - 0.1%	0.1%	Drops solution	524,099 L.L
S01GX09	OLOPAT UD	G	Olopatadine (HCl) - 0.1%	0.1%	Drops solution	1,523,917 L.L
R01AA07	OTRIVIN	B	Xylometazoline HCl - 0.1%	0.1%	Solution	260,705 L.L
R01AA07	OTRIVIN	B	Xylometazoline HCl - 0.1%	0.1%	Drops	241,892 L.L
R01AA07	OTRIVIN MENTHOL 0.1%	B	Xylometazoline HCl - 0.1%	0.1%	Drops	387,027 L.L
S01BA07	OPTILONE	G	Fluorometholone - 0.1%	0.1%	Solution	309,084 L.L
A11CC03	ONE-ALPHA	B	Alfacalcidol - 0.25mcg	0.25mcg	Capsule	1,138,235 L.L
A10BJ06	OZEMPIC	B	Semaglutide - 0.25mg	0.25mg	Injectable solution	10,927,526 L.L
H01CC01	ORGALUTRAN	B	Ganirelix - 0.25mg/0.5ml	0.25mg/0.5ml	Injectable solution	2,383,977 L.L
H01CC01	ORGALUTRAN	B	Ganirelix - 0.25mg/0.5ml	0.25mg/0.5ml	Injectable solution	2,383,977 L.L
S01AE01	OFLOX	B	Ofloxacin - 3mg/ml	0.3%	Drops solution	366,869 L.L
S01AE01	OFLOX	B	Ofloxacin - 0.3%	0.3%	Drops solution	366,869 L.L
R06AD08	OXOMIL	G	Oxomemazine HCl - 0.33mg/ml	0.33mg/ml	Syrup, sugar free	511,940 L.L
R06AD08	OXOMEMAZINE ARROW	G	Oxomemazine HCl - 0.33mg/ml	0.33mg/ml	Syrup	431,373 L.L
R06AD08	OXOMEMAZINE ARROW	G	Oxomemazine HCl - 0.33mg/ml	0.33mg/ml	Solution, sugar free	431,373 L.L
G04CA02	OMNIC OCAS	B	Tamsulosin HCl - 0.4mg	0.4mg	Tablet, film coated, prolonged release	866,778 L.L
A11CC03	ONE-ALPHA	B	Alfacalcidol - 0.5mcg	0.5mcg	Capsule	943,377 L.L
A11CC03	ONE-ALPHA	B	Alfacalcidol - 0.5mcg	0.5mcg	Capsule	942,034 L.L
A10BJ06	OZEMPIC	B	Semaglutide - 0.5mg	0.5mg	Injectable solution	10,927,526 L.L
R06AX27	ORADUS	G	Desloratadine - 0.5mg/ml	0.5mg/ml	Solution	199,657 L.L
G03CA03	OESTRACLIN	G	Estradiol - 0.6mg/g	0.6mg/g	Gel	448,843 L.L
S01AA13	OPTIFUCIN VISCOUS	G	Fusidic acid - 1%	1%	Drops	208,296 L.L
M02AA15	OLFEN	G	Diclofenac sodium (diethylamine) - 1%	1%	Gel	268,769 L.L
B02BD02	OCTANATE	BioHuman	Coagulation Factor VIII - 1,000IU	1,000IU	Injectable lyophilised powder for solution+diluent	46,817,511 L.L
J01CA04	OSPAMOX	G	Amoxicillin (trihydrate) - 1g	1,000mg	Tablet, film coated	683,273 L.L
A11CC05	ORAVIL	G	Vitamin D3 - 100,000IU/2ml	100,000IU	Solution	618,168 L.L

...